








































Regulation of calcium homeostasis and bone 
metabolism is the most widely recognized function of 
1,25-dihydroxyvitamin D3 also known as calcitriol 
(1,25-VD), the hormonal form of vitamin D. However, 
there is a growing body of evidence showing that 1,25-
VD also plays a significant role in the prevention of 
different types of cancer [1-9]. The molecular 
mechanisms that may be involved in the chemo-
preventive and antitumor activities of 1,25-VD have 
been extensively reviewed in recent publications 
[3,9,10].  One of the mechanisms that may contribute to  
 
 








































the chemo-preventive properties of 1,25-VD is 
modulation of the DNA damage response that facilitates 
successful DNA repair after treatment with genotoxic 
agents [10-16]. This mechanism was observed 
particularly after exposure of cells to UV light [11-14]. 
Recent studies on gene profiling revealed that the DNA 
repair genes are among a multitude of genes whose 
transcription is induced by 1,25-VD [17-19].  
 
Another mechanism that may contribute to the chemo-
preventive properties of 1,25-VD is likely provided by 
its antioxidant activity. Persistent DNA damage by 
endogenous oxidants, by-products of aerobic 
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carcinogenesis and aging [20-24]. Accumulated 
genomic mutations from improperly repaired DNA, 
particularly at the sites of oncogenes or tumor 
suppressor genes, may result in malignant 
transformation. There is ample evidence that 1,25-VD 
provides protection against oxidative DNA damage. 
Thus, constitutive DNA damage in colon epithelium, 
likely induced by endogenous oxidants, was seen to be 
elevated in vitamin D receptor (VDR)-knockout mice 
[25]. Conversely, the treatment of humans with a daily 
dose of 800 I.U. of vitamin D was shown to reduce 
oxidative DNA damage in colon epithelium [26]. 
Treatment of cells of several cell lines with 1,25-VD led 
to induction of enzymes involved in protection against 
oxidative damage. One of them is thioredoxin reductase 
1 (TXNRD1), the enzyme which maintains thioredoxin 
in the reduced state needed to confer a reduced 
intracellular redox state and thereby limit intracellular 
oxidant stress [27-30]. Another antioxidant protein 
induced by 1,25-VD is superoxide dismutase (SOD) 
[28-31]. 
 
We have recently reported that untreated normal or 
tumor cells in culture exhibit a “background” level of 
DNA damage signaling (DDS) revealed as histone 
H2AX phosphorylation on Ser139 and activation of 
Ataxia Telangiectasia  mutated protein kinase (ATM) 
through phosphorylation on Ser1981 [32-34]. These 
phosphorylation events, which report DNA damage and 
in particular formation of DNA double-strand breaks 
(DSBs) [35,36], were detected in individual cells 
immunocytochemically using phospho-specific Abs and 
measured by flow and laser scanning cytometry (LSC) 
32-34]. Multiparameter cytometric analysis made it 
possible to correlate the level of this intrinsic, 
constitutive DDS, with the cell cycle phase and with the 
cell’s propensity to undergo apoptosis. In a series of 
experiments we demonstrated that, at least to a large 
degree, the constitutive DDS is in response to oxidative 
DNA damage induced by endogenous oxidants 
produced during aerobic respiration [32-34]. Mitogenic 
stimulation of lymphocytes dramatically increased the 
level of constitutive DDS concurrent with an increase in 
the generation of endogenous oxidants and activation of 
the mTOR pathway [37]. Conversely, prolonged 
exposure of cells to agents that reduced the level of 
endogenous oxidants such as hyaluronan [38], or to 
metformin, the anti-diabetic drug, inducer of AMP-
activated protein kinase and mTOR suppressor [39], led 
to a significant attenuation of constitutive DDS. In light 
of previous evidence for the antioxidant and chemo-
preventive properties of 1,25-VD, in the present study 
we explored whether this vitamin/hormone has the 
ability to affect the level of constitutive DDS.  
RESULTS 
 
Exposure of A549 cells to 1,25-VD at a concentration 
of 2 or 10 nM for 24 and 48 h led to a distinct reduction 
in the level of expression of γH2AX (Figure 1). As it is 
evident from the bivariate DNA content versus γH2AX 
expression dotplots, the degree of decline in γH2AX 
expression was similar regardless of 1,25-VD 
concentration and duration of cell treatment. However, 
a distinct difference was apparent with regard to cell 
cycle phase. The cells most affected were in S-phase of 
the cell cycle which showed a reduction in γH2AX 
within the range of 36% to 39%. The effect of 1,25D 
was less pronounced in the case of G1 or G2M phase 
cells as their γH2AX expression was decreased by only 
18-22% or 11-21%, respectively. During the time and at 
the concentration of 1,25-VD studied here, there was no 
detectable effect on the cell cycle distribution of A549 
cells, as is evident from the similarity of the cellular 
DNA content histograms shown in the respective insets.    
  
Figure 2 illustrates the effect of 1,25-VD on the level of 
phosphorylation of ATM at S1981 in A549 cells. As in 
the case of H2AX phosphorylation (Figure 1), the 
expression of S1981 phosphorylated ATM was 
markedly reduced in cells exposed to 1,25-VD. The 
degree of decline in expression of phosphorylated ATM 
was similar at 2 nM and at 10 nM of vitamin D and 
following 24 h or 48 h of exposure. As compared with 
the effect of 1,25-VD on γH2AX expression (Figure 1) 
there were less pronounced differences in the degree of 
reduction of ATM-S1981
P between the cells in different 
phases of the cell cycle. However, the cells in S phase 
were somewhat more affected (33% - 43% reduction) 
compared to G1 (30-35%) or G2M cells (17-30%), 
respectively. 
  
Treatment of human B lymphoblastoid TK6 cells with 
1,25-VD also led to a decrease in the level of 
constitutive expression of γH2AX and ATM-S1981
P 
(Figure 3). The overall effect of 1,25-VD in suppression 
of the level of constitutive phosphorylation of these 
proteins in TK6 cells was somewhat weaker than in 
A549 cells (Figures 1 and 2). However, as in the case of 
A549 cells, the S-phase cells were more affected by 
1,25-VD than G1 or G2M phase cells in TK6 cultures 
and the suppressive effect of 1,25-VD on H2AX 
phosphorylation (13-18%) was more pronounced than 
on phosphorylation of ATM (8-12%). 
 
We have also tested the effect of 1,25-VD on the level 
of constitutive expression of γH2AX and ATM-S1091
P 
in proliferating human lymphocytes (Figure 4). In the 
initial experiments we noticed that when 1,25-VD was 
added into cultures concurrent with PHA, lymphocyte 
   
www.impactaging.com                    271                                            AGING, April 2012, Vol.4 No.4stimulation, as expressed by the increases in cellular 
RNA content and progression through the cell cycle, 
was delayed compared to cells growing in the absence 
of 1,25-VD. This observation was consistent with prior 
studies that showed the suppressive effect of 1,25-VD 
on lymphocyte stimulation by a variety of mitogens [41-
43]. However, when lymphocytes were already fully in 
the cell cycle 48 h following stimulation by PHA, the 














































progression over the subsequent 24 h. Under such 
conditions, we were able to test the effect of 1,25-VD 
on constitutive expression of γH2AX and ATM-S1981
P 
on cells which had fully entered the cell cycle similar to 
the cells stimulated by PHA growing in the absence of 
1,25-VD (Figure 4A). Therefore, the results were not 
biased by the anti-proliferative effect of 1,25D which 
would have been apparent if 1,25-VD had been added 
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scatterplots), the data on lymphocytes are presented as 
bar graphs (Figure 4). The effect of 1,25-VD on 
lymphocytes was similar to that its effect on A549 or 
TK6 cells. As it is evident, the level of expression of 
γH2AX was distinctly lower in the 1,25-VD treated 
cells (Fig 4A). The cells most affected were in S-phase, 
where  γH2AX fluorescence was decreased by 40%, 
nearly twice as much as that of G1 or G2M cells. The 
level of expression of ATM-S1981
P was also decreased 
in 1,25-VD treated lymphocytes, but the decrease was 
less pronounced (10-18% across all phases of the cell 
cycle) compared to that of γH2AX (data not shown). 
 
In another set of lymphocyte cultures, we explored 
whether 1,25-VD can affect expression of γH2AX upon 
induction of oxidative damage by H2O2. Towards this 
end, lymphocytes stimulated by PHA for 48 h and then 
treated with 1,25-VD for an additional 24 h were 
exposed to 200 μM H2O2 (+ 1,25-VD) for 60 min; 
parallel cultures of PHA stimulated lymphocytes were 
exposed to 200 μM H2O2 for 60 min without 
pretreatment with 1,25-VD (H2O2) (Figure 4B). The 
cells treated only with H2O2 had approximately a two-
fold higher level of γH2AX expression compared with 





























of oxidative DNA damage by the peroxide [40]. 
However, the effect of treatment with H2O2 in terms of 
a decline in expression of γH2AX was less pronounced 
in the cells exposed to 1,25-VD. Specifically, compared 
with the cells not treated with 1,25-VD, the treated cells 
exhibited an 18-26% lower level of γH2AX expression 
in which the S phase cells were more affected compared 
to G1 or G2M phase cells. 
 
In addition to measuring the effect of 1,25-VD on 
expression of γH2AX and ATM-S1981
P in lymphocytes 
we have also measured the effect of this hormone on the 
intracellular level of ROS as detected by the 
lymphocytes’ ability to oxidize dihydrofluorescein. This 
reagent (2,7-dichlorodihydrofluorescein diacetate; 
DCFH-DA) is permeant and non-fluorescent but when 
oxidized within the cell becomes fluorescent. Exposure 
of PHA-stimulated lymphocytes to 10 nM 1,25-VD for 
24 h and 48 h (as described in Materials and Methods) 
reduced by about half (from 62 ± 3.5 to 32 ± 4.7 AU) or 
by nearly three-fold (from 62 ± 3.5 to 23 ± 4.7) their 
ability to oxidize DCFH-DA, respectively. However, 
we were not able to observe a significant reduction of 
DCFH-DA fluorescence in TK6 or A549 cells treated 
for 24 h with 2 nM or 10 nM 1,25-VD (data not 







































































The present data show that the level of constitutive 
DNA damage signaling as measured by expression of 
γH2AX and ATM-S1981
P was decreased in A549 and 
TK6 tumor cells cultured in the presence of 1,25-VD for 
24 – 48 h. Also decreased was the level of γH2AX and 
ATM-S1981
P in proliferating normal human 
lymphocytes cultured in the presence of 1,25-VD. 
These data suggest that both in normal proliferating 
lymphocytes as well as in A549 or TK6 tumor cells the 
level of constitutive DNA damage, likely induced by-
products of oxidative metabolism was attenuated by 
1,25-VD. Several mechanisms may be responsible for 
this effect. 
 
It has been observed that the level of constitutive DNA 
damage signaling is more pronounced in S and G2M 
than in G1-phase cells [32-34]. This level was also seen 
to dramatically increase during mitogenic stimulation of 
lymphocytes [37]. Most likely, the high intensity of 
constitutive DNA damage signaling in S-phase cells is 
reporting DNA replication stress that occurs when 
replication forks encounter sites of DNA with oxidative 
damage. Replication stress, especially combined with 
mTOR activation can lead to elevated levels of DNA 
damage signaling (“pseudo-DNA damage response”) 
associated with cell senescence [39,44-47]. The 
suppressive effect on H2AX and ATM phosphorylation 
by 1,25-VD, as is evident in S-phase cells, suggests that 
in cells exposed to this hormone the intensity of 
replication stress is greatly diminished. Consistent with 
this is the evidence that in some cell types 1,25-VD 
suppresses Akt/mTOR signaling [48-50]. It should be 
noted, however, that in leukemic cells triggered by 
1,25-VD to differentiation, the PI3K/Akt pathway is 
actually activated, making the association between these 
pathways and biological effects complex [51,52]. It is 
possible that activation of the PI3K/AKT/mTOR 
pathway takes place exclusively after induction of 
differentiation of promyelocytic leukemic (HL-60) cells 
whereas in other cell systems, when differentiation is 
not apparent, mTOR is inhibited by this hormone. 
Interestingly, inhibition of mTORC1 by the rapamycin 
analog RAD001 was shown to potentiate the effect of 
1,25-VD to induce growth arrest and differentiation in 
AML cells, which prompted the authors to propose the 
strategy of concomitant administration of both 1,25-VD 
and an mTOR inhibitor in treatment of AML [53]. The 
anti-aging properties of vitamin D [54-58] would be 
consistent with its mTOR inhibitory activity [47,59]. 
  
The attenuation of DNA damage signaling by 1,25-VD 
in lymphocytes as seen in the present study would also 
be consistent with the anti-oxidant properties of this 
hormone [25-31]. Indeed we observed that exposure of 
lymphocytes to 1,25-VD led to a decrease in abundance 
of reactive oxidants that were detected by their ability to 
oxidize DCFH-DA. We were unable, however, to see a 
significant effect following exposure of TK6 or A549 
cells for 24 h to 1,25-VD on oxidation of DCFH-DA. 
Yet, at the same time a reduction in the constitutive 
level of γH2AX in these cells was observed. While it is 
possible that the sensitivity of the DCFH-DA-ROS 
detection assay is inadequate to reveal minor changes in 
abundance of endogenous oxidants that still affect the 
level of constitutive H2AX phosphorylation, factors 
other than ROS induced by 1,25-VD may contribute to 
the lowering DNA damage signaling. 
 
Our present findings are in accord with the recently 
published data of Ting et al., [60] in a mouse model 
system which show that 1,25-VD reduces the level of 
H2AX phosphorylation and ATM activation after 
induction of DNA damage by H2O2 or by N-nitroso-N-
methylurea (NMU). Of interest are also their findings 
that 1,25-VD enhanced expression of DNA repair genes 
 
Figure 4. Effect of treatment of mitogenically stimulated
proliferating  human  lymphocytes  untreated  or  treated
with  H2O2  and  1,25‐VD  on  the  level  of  expression  of






of γ H2AX  was  detected  immunocytochemically  and  cell
fluorescence was measured by flow cytometry. Through gating
analysis  (as  shown  in  Figs.  1‐  3)  the  mean  values  (+SD)  of
fluorescence intensity for cells in G1, S and G2M phases of the
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stress and malignant transformation. The mechanism 
advanced by the authors involves the cross-talk between 
ATM and 1,25-VD receptor (VDR). Specifically, 
activation of ATM, the early step in the DNA damage 
response pathway, in the presence of 1,25-VD leads to 
phosphorylation of VDR, which in turn induces 
transcriptional upregulation of ATM and RAD50 
thereby promoting effective DSB repair [60]. With such 
interactions between ATM and VDR, one would expect 
that 1,25-VD may affect downstream pathways such as 
those leading to apoptosis and cell senescence, thereby 
providing a barrier to cancer development, and 
protecting genome integrity. The interactions between 
ATM and VDR may also be the mechanism that 
explains our data on reduction of constitutive H2AX 
phosphorylation (likely reporting the presence of DSBs) 
in A549 and TK6 cells in the absence of detectable 
effect of 1,25-VD on ROS. According to this 
mechanism [60] it is feasible that constitutive activation 
of ATM in the presence of 1,25-VD induces 
phosphorylation of VDR which further enhances 
expression of ATM and RAD50, leads to a more 
effective DNA repair, reduces  frequency of DSBs and, 
as a consequence, dampens down the level of DNA 
damage signaling (γH2AX expression). 
     
It has been reported that proliferation of cells from 
various solid tumor types including malignant 
melanoma [61], colon [62], breast [63] and prostate 
cancer [64] is inhibited by 1,25-VD. Vitamin D and its 
analogues are also widely recognized as potential 
anticancer drugs in the treatment of some hematological 
malignancies [2,9]. It is unclear if there is an association 
between molecular mechanisms responsible for the 
presently observed attenuation of constitutive DNA 
damage signaling and the previously reported effects of 
1,25-VD on cell survival. For instance, in myeloid 
leukemia cells in culture 1,25-VD affects cell survival 
by upregulation of the AKT [52], and the KSR2 
pathways [65].  Most recently, the upregulation of 
microRNA32 expression by 1,25-VD was shown to 
control the levels of the pro-apoptotic protein BIM [66]. 
These molecules could be components of a complex 
network that orchestrates cell survival at the level of 
DNA damage. However, the attenuation of DNA 
damage response (DDR) by 1,25-VD demonstrated here 
illustrates that DDR can be a barrier, or a pathway, to 
tumor progression, depending on the presence and 
nature of extracellular factors [67,68]. 
 
MATERIALS AND METHODS 
 
Cells, Cell Treatment. Human lung carcinoma A549 
cells, were obtained from the American Type Culture 
Collection (ATCC, Manassas,VA). Human B-cell 
lymphoblastoid TK6 cells were kindly provided by Dr 
Howard Liber of Colorado State University (Fort 
Collins CO). Human peripheral blood lymphocytes 
were obtained by venipuncture from healthy volunteers 
following informed consent according to Institutional 
guidelines, and isolated by density gradient 
centrifugation. A549 cells were cultured in Ham’s 
F12K, TK6 and lymphocytes were cultured in RPMI 
1640 with 2 mM L-glutamine adjusted to contain 1.5 
g/L sodium bicarbonate supplemented with 10% fetal 
bovine serum (GIBCO/Invitrogen, Carlsbad, CA). 
Adherent A549 cells were grown in dual-chambered 
slides (Nunc Lab-Tek II), seeded with 10
5 cells/ml 
suspended in 2 ml medium per chamber. TK6 cells and 
lymphocytes were grown in suspension; lymphocyte 
cultures were treated with the polyvalent mitogen 
phytohemaglutinin (Sigma /Aldrich; St Louis, MO) as 
described [37]. The active form of vitamin D, 1,25-VD, 
was kindly provided by Dr. Milan Uskokovic, and the 
stock solution was maintained in ethanol. During 
treatment with 1,25-VD the cells were in exponential 
phase of growth; control cells were treated with an 
equivalent concentration of ethanol. After exposure to 
1,25-VD at various concentrations and for specified 
periods of time (as shown in figure legends) the cells 
were rinsed with phosphate buffered salt solution (PBS) 
and fixed in 1% methanol-free formaldehyde 
(Polysciences, Warrington, PA) for 15 min on ice The 
cells were then transferred to 70% ethanol and stored at 
-20 
oC for up to 3 days until staining. 
 
Detection of H2AX Phosphorylation and ATM 
Activation.  The cells were washed twice in PBS and 
with 0.1% Triton X-100 (Sigma) in PBS for 15 min and 
with a 1% (w/v) solution of bovine serum albumin 
(BSA; Sigma) in PBS for 30 min to suppress 
nonspecific antibody (Ab) binding. The cells were then 
incubated in 1% BSA containing a 1:300 dilution of 
phospho-specific (Ser139) γH2AX mAb (Biolegend, 
San Diego, CA) or with a 1:100 dilution of phospho-
specific (Ser1981) ATM mAb (Millipore, Tamecula, 
CA).  The secondary Ab was tagged with AlexaFluor 
488 fluorochrome (Invitrogen/Molecular Probes, used at 
1:200 dilution). Cellular DNA was counterstained with 
2.8  μg/ml 4,6-diamidino-2-phenylindole (DAPI; 
Sigma). Each experiment was performed with an IgG 
control in which cells were labeled only with the 
secondary AlexaFluor 488 Ab, without primary Ab 
incubation to estimate the extent of nonspecific 
adherence of the secondary Ab to the cells. The 
fixation, rinsing and labeling of A549 cells was carried 
out on slides, and lymphocytes and TK6 cells in 
suspension. Other details have been previously 
described [39,40].   
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cells as well as cells treated with vitamin D were 
incubated 60 min with 10 μM 2',7'-dihydro-
dichlorofluorescein-diacetate (H2DCF-DA) (Invitrogen/ 
Molecular Probes) at 37˚C. Cellular green fluorescence 
was then measured by flow cytometry. Following 
oxidation by ROS and peroxides within cells the non-
fluorescent substrate H2DCF-DA is converted to the 
highly fluorescent derivative DCF [59].  
 
Analysis of Cellular Fluorescence. A549 cells: Cellular 
immunofluorescence representing the binding of the 
respective phospho-specific Abs as well as the blue 
emission of DAPI stained DNA was measured by Laser 
Scanning Cytometry (LSC) [70]  (iCys; CompuCyte, 
Westwood, MA) utilizing standard filter settings; 
fluorescence was excited with 488-nm argon, helium-
neon (633 nm) and violet (405 nm) lasers. The 
intensities of maximal pixel and integrated fluorescence 
were measured and recorded for each cell. At least 
3,000 cells were measured per sample. Gating analysis 
was carried out as described in Figure legends. TK6 
cells and lymphocytes:  Cellular fluorescence was 
measured by using a MoFlo XDP (Beckman-Coulter, 
Brea, CA) high speed flow cytometer/sorter. DAPI 
fluorescence was excited with the UV laser (355-nm), 
AlexaFluor 488 and DCF with the argon ion (488-nm) 
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